Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 25

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 25
---
Item 3. Key Information – D. Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which is incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. You should be able to bear a complete loss of your investment.

Risks Related to the Offering

It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Shareholder, or the actual gross proceeds resulting from those sales.

On March 31, 2025, we entered
into the Purchase Agreement with the Selling Shareholder, pursuant to which the Selling Shareholder has committed to purchase up to $25.0
million of our Common Shares, subject to certain limitations and conditions set forth in the Purchase Agreement. Of the Total Commitment,
to date, we have not sold any Common Shares (other than the Commitment Shares). The Common Shares that may be issued under the Purchase
Agreement may be sold by us to the Selling Shareholder at our discretion from time-to-time over a 36-month period commencing on the date
of the Purchase Agreement.

We generally have the right
to control the timing and amount of any sales of our Common Shares to the Selling Shareholder under the Purchase Agreement. Sales of our
Common Shares, if any, to the Selling Shareholder under the Purchase Agreement will depend upon market conditions and other factors. We
may ultimately decide to sell to the Selling Shareholder all, some or none of the Common Shares that may be available for us to sell to
the Selling Shareholder pursuant to the Purchase Agreement.

Because the purchase price
per share to be paid by the Selling Shareholder for the Common Shares that we may elect to sell to the Selling Shareholder under the Purchase
Agreement, if any, will fluctuate based on the market prices of Common Shares during the applicable purchase valuation period for each
purchase made pursuant to the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and
prior to any such sales, the number of Common Shares that we will sell to the Selling Shareholder under the Purchase Agreement, the purchase
price per share that the Selling Shareholder will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross
proceeds that we will receive from those purchases by the Selling Shareholder